Ricardo López Almaraz

Dr. Ricardo López Almaraz

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
PRPaula Rio
Paula Rio
SNSusana Navarro
Susana Navarro
WWWei Wang
Wei Wang
RSRebeca Sánchez-Domínguez
Rebeca Sánchez-Domínguez
RPRoser M. Pujol
Roser M. Pujol
JBJuan A Bueren
Juan A Bueren

1 August 2020 in Journal of Hepatology
Verified
Journal Article
Open access
JCJuan Carrillo-Reixach
Juan Carrillo-Reixach
LTLaura Torrens
Laura Torrens
MSMarina Simon-Coma
Marina Simon-Coma
LRLaura Royo
Laura Royo
MDMontserrat Domingo-Sàbat
Montserrat Domingo-Sàbat
CACarolina Armengol
Carolina Armengol
Hepatoblastoma (HB) is a rare disease. Nevertheless, it is the predominant pediatric liver cancer, with limited therapeutic options for patients with aggressive tumors. Here we sought to increase knowledge of HB pathobiology in an effort to move towards precision medicine. To this end, we used high-throughput technologies to identify new biomarkers and therapeutic targets for HB patients with poor prognosis METHODS: We performed a comprehensive genomic, transcriptomic and epigenomic characterization of 159 clinically-annotated samples from 113 HB patients RESULTS: We discovered an unprecedented widespread epigenetic footprint of HB that includes hyperediting of the tumor suppressor BLCAP concomitant with a genome-wide dysregulation of RNA editing and the overexpression of mainly non-coding genes of the oncogenic 14q32 DLK1-DIO3 locus. By unsupervised analysis, we identified two epigenomic clusters (Epi-CA, Epi-CB) with distinct degree of DNA hypomethylation and CpG island hypermethylation that are associated with the C1/C2/C2B transcriptomic subtypes. Based on these findings, we defined the first Molecular Risk Stratification of HB (MRS-HB), which encompasses three main prognostic categories and improves the current clinical risk stratification approach. The MRS-3 category (28%), defined by strong 14q32 locus expression and Epi-CB methylation features, was characterized by CTNNB1 and NFE2L2 mutations, a progenitor-like phenotype and clinical aggressiveness. Finally, we identified choline kinase alpha as a promising therapeutic target for intermediate and high-risk HBs since its inhibition in HB cell lines and patient-derived xenografts strongly abrogated tumor growth CONCLUSIONS: Our findings expand our knowledge about the molecular features of HB and may contribute to improve current clinical stratification approaches and treatments to increase the survival of patients with HB.

1 November 2015 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
DHDirk Holzinger
Dirk Holzinger
SFSelina Kathleen Fassl
Selina Kathleen Fassl
WJWilco de Jager
Wilco de Jager
PLPeter Lohse
Peter Lohse
URUte Röhrig
Ute Röhrig
JRJohannes Roth
Johannes Roth

28 June 2011 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
SRSusana Rives
Susana Rives
JEJesús Estella
Jesús Estella
PGPedro Gómez
Pedro Gómez
MLMónica López‐Duarte
Mónica López‐Duarte
PMPurificación García de Miguel
Purificación García de Miguel
IBIsabel Badell
Isabel Badell
Summary: Philadelphia‐chromosome acute lymphoblastic leukaemia (Ph+ ALL) is a subgroup of ALL with very high risk of treatment failure. We report here the results of the Sociedad Española de Hematología y Oncología Pediátricas (SEHOP/SHOP) in paediatric Ph+ ALL treated with intermediate‐dose imatinib concurrent with intensive chemotherapy. The toxicities and outcome of these patients were compared with historical controls not receiving imatinib. Patients with Ph+ ALL aged 1–18 years were enrolled in three consecutive ALL/SHOP trials (SHOP‐94/SHOP‐99/SHOP‐2005). In the SHOP‐2005 trial, imatinib (260 mg/m2 per day) was given on day‐15 of induction. Allogeneic haematopoietic stem‐cell transplantation (HSCT) from a matched related or unrelated donor was scheduled in first complete remission (CR1). Forty‐three patients were evaluable (22 boys, median age 6·8 years, range, 1·2–15). Sixteen received imatinib whereas 27 received similar chemotherapy without imatinib. Seventeen of 27 and 15 of 16 patients in the non‐imatinib and imatinib cohort, respectively, underwent HSCT in CR1. With a median follow‐up of 109 and 39 months for the non‐imatinib and imatinib cohorts, the 3‐year event‐free survival (EFS) was 29·6% and 78·7%, respectively (P = 0·01). These results show that, compared to historical controls, intermediate dose of imatinib given concomitantly with chemotherapy and followed by allogeneic HSCT markedly improved early EFS in paediatric Ph+ ALL.

5 October 2019 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
MBMassimo Bogliolo
Massimo Bogliolo
RPRoser Pujol
Roser Pujol
MAMiriam Aza-Carmona
Miriam Aza-Carmona
NMNúria Muñoz-Subirana
Núria Muñoz-Subirana
BRBenjamin Rodriguez-Santiago
Benjamin Rodriguez-Santiago
JSJordi Surralles
Jordi Surralles
Purpose: Patients with Fanconi anaemia (FA), a rare DNA repair genetic disease, exhibit chromosome fragility, bone marrow failure, malformations and cancer susceptibility. FA molecular diagnosis is challenging since FA is caused by point mutations and large deletions in 22 genes following three heritability patterns. To optimise FA patients’ characterisation, we developed a simplified but effective methodology based on whole exome sequencing (WES) and functional studies.Methods: 68 patients with FA were analysed by commercial WES services. Copy number variations were evaluated by sequencing data analysis with RStudio. To test FANCA missense variants, wt FANCA cDNA was cloned and variants were introduced by site-directed mutagenesis. Vectors were then tested for their ability to complement DNA repair defects of a FANCA-KO human cell line generated by TALEN technologies.Results: We identified 93.3% of mutated alleles including large deletions. We determined the pathogenicity of three FANCA missense variants and demonstrated that two FANCA variants reported in mutations databases as ‘affecting functions’ are SNPs. Deep analysis of sequencing data revealed patients’ true mutations, highlighting the importance of functional analysis. In one patient, no pathogenic variant could be identified in any of the 22 known FA genes, and in seven patients, only one deleterious variant could be identified (three patients each with FANCA and FANCD2 and one patient with FANCE mutations)Conclusion: WES and proper bioinformatics analysis are sufficient to effectively characterise patients with FA regardless of the rarity of their complementation group, type of mutations, mosaic condition and DNA source.

5 March 2019 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
JGJose Genolla
Jose Genolla
TRTrinidad Rodriguez
Trinidad Rodriguez
PMPablo Minguez
Pablo Minguez
RARicardo López Almaraz
Ricardo López Almaraz
VLVeronica Llorens
Veronica Llorens
AEAizpea Echebarria
Aizpea Echebarria